Presentation is loading. Please wait.

Presentation is loading. Please wait.

Christopher G. Slatore, MD, MS, David H

Published byAndra Banks Modified over 6 years ago

Similar presentations

Presentation on theme: "Christopher G. Slatore, MD, MS, David H"— Presentation transcript:

1 Cost-Effectiveness of a Smoking Cessation Program Implemented at the Time of Surgery for Lung Cancer 
Christopher G. Slatore, MD, MS, David H. Au, MD, MS, William Hollingworth, PhD  Journal of Thoracic Oncology  Volume 4, Issue 4, Pages (April 2009) DOI: /JTO.0b013e318195e23a Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 It shows the decision tree developed from the available evidence. Patients diagnosed with resectable stage IIIB or less non-small cell lung cancer are offered a smoking cessation program or usual care. Each number represents the probability of progressing to one stage or the other. Periop, perioperative. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 It shows the 5-year postsurgery differences in cost/quality adjusted life years (QALY) and cost/life year as the proportion of recent quitters who suffer perioperative complications increases over the rate of continued smokers with perioperative complications. Note that the base case assumes no difference in the proportions suffering perioperative complications. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 It shows the 5-year postsurgery differences in cost/quality adjusted life years (QALY) and cost/life year as the cost of the smoking cessation program changes. Note that the base case has a cost of approximately $200. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 It shows the 5-year postsurgery differences in cost/quality adjusted life years (QALY) and cost/life year as the effectiveness of the smoking cessation program changes. Note that the base case assumes the smoking cessation program leads to an increase of 7% of the subjects achieving abstinence at 3 months postsurgery. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 It shows the 5-year postsurgery differences in cost/quality adjusted life years (QALY) and cost/life year as the proportion of smokers who are deceased at 1 year after surgery increases over the proportion of recent quitters who are deceased. Note that the base case assumes that smokers have a 12% higher proportion who are deceased at 1 year compared with recent quitters. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6 It shows the 5-year postsurgery differences in cost/quality adjusted life years (QALY) as the utility of smokers changes with respect to quitters. Note that the base case assumes that quitters have a utility score 0.15 higher than smokers. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e318195e23a) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Christopher G. Slatore, MD, MS, David H"

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure  Jessamy A. Boyd, MD, Jessica L. Hubbs,

Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure  Jessamy A. Boyd, MD, Jessica L. Hubbs,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.

Similar presentations

Ads by Google